Array biopharma to report financial results for the fourth quarter and full year of fiscal 2012 on august 13, 2012

Boulder, colo.--(business wire)--array biopharma inc. (nasdaq:arry) will report financial results for the fourth quarter and full year of fiscal 2012 on monday, august 13, 2012, and will hold a conference call on tuesday, august 14, 2012 at 9:00 a.m. eastern time to discuss these results. ron squarer, chief executive officer and michael carruthers, chief financial officer will lead the call. conference call information date: time: toll-free: toll: pass code: webcast & conference call slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome a replay of the call will be available as a webcast on www.arraybiopharma.com. about array biopharma array biopharma inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. array has four core proprietary clinical programs: arry-614 for myelodysplastic syndromes, arry-520 for multiple myeloma, arry-797 for pain and arry-502 for asthma. in addition, array has 10 partner-funded clinical programs including two mek inhibitors in phase 2: selumetinib with astrazeneca and mek162 with novartis. for more information on array, please go to www.arraybiopharma.com.
ARRY Ratings Summary
ARRY Quant Ranking